Merlin Nexus And New Leaf Venture Partners Comment On Extension Of Tender Offer Deadline In Conjunction With Pfizer's Proposed $56 Million Acquisition Of Icagen
NEW YORK, Sept. 1, 2011 /PRNewswire/ -- Merlin Nexus and New Leaf Venture Partners (NLV Partners) provided comment today regarding Pfizer Inc's (NYSE: PFE) announcement it had extended the deadline of its all-cash tender offer for Icagen's (Nasdaq: ICGN) shares to Thursday, September 1 at midnight:
"Merlin Nexus and NLV Partners, both stockholders in Icagen, believe strongly that Pfizer's proposed acquisition of Icagen at the price of $6 per share greatly undervalues the potential that we see for Icagen as a whole and for the company's development pipeline," Dominique Semon, Managing Partner of Merlin Nexus, and Philippe Chambon, Managing Director, NLV Partners, commented in a joint statement. "We are pleased to see that other stockholders agree and therefore Pfizer has not received sufficient shares to complete its acquisition of Icagen at the proposed price at this time."
Mr. Semon and Dr. Chambon added, "Merlin Nexus and NLV Partners continue to oppose the acquisition as proposed at this price, and we do not intend to tender our Icagen shares to Pfizer under the current terms."
In the past two months, Merlin Nexus and NLV Partners have distributed three letters contesting the price of the acquisition proposed by Pfizer. The most recent letter stated that although the aggregate value of the proposed transaction is approximately $56 million, "the true cost to Pfizer to acquire the company's assets is only $22 million when near-term R&D and milestone payments as well as the cash Icagen currently owns are put into the equation. This cost would be even lower if the Pfizer-Icagen R&D collaboration were renewed after it expires later this year."The letter also referenced conservative estimates of the value of Icagen's pain programs alone at as much as $100-$165 million or $11-$19 a share. In December 2010, Pfizer advanced the first of Icagen's proprietary compounds (PF-05089771) into a phase I single dose escalation study, and this trial was expected to have been completed in March 2011. According to the letter to Icagen shareholders, "trial data are open to Pfizer as they are required to monitor safety. These data provide Pfizer with an unfair advantage not afforded to all investors to determine the value of this program." About Merlin Nexus Merlin Nexus, based in New York, is an investment management company focused on crossover private equity investing in the life sciences industry. Merlin Nexus invests globally in private and public healthcare companies and manages several crossover private equity funds with capital commitments totaling $200 million. Our investor base consists of financial institutions, funds of funds, family offices and high net worth individuals. About NLV Partners New Leaf Venture Partners is a leader in healthcare technology venture investing. Our investment professionals bring a unique blend of technological, clinical, and operational experience to our investments. We work closely with our entrepreneurs to help build successful portfolio companies. We focus primarily on later-stage biopharmaceutical products, early-stage medical devices, and laboratory infrastructure technologies.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV